Literature DB >> 21753160

Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy.

D M Escolar1, L P Hache, P R Clemens, A Cnaan, C M McDonald, V Viswanathan, A J Kornberg, T E Bertorini, Y Nevo, T Lotze, A Pestronk, M M Ryan, E Monasterio, J W Day, A Zimmerman, A Arrieta, E Henricson, J Mayhew, J Florence, F Hu, A M Connolly.   

Abstract

OBJECTIVE: To perform a double-blind, randomized study comparing efficacy and safety of daily and weekend prednisone in boys with Duchenne muscular dystrophy (DMD).
METHODS: A total of 64 boys with DMD who were between 4 and 10 years of age were randomized at 1 of 12 centers of the Cooperative International Neuromuscular Research Group. Efficacy and safety of 2 prednisone schedules (daily 0.75 mg/kg/day and weekend 10 mg/kg/wk) were evaluated over 12 months.
RESULTS: Equivalence was met for weekend and daily dosing of prednisone for the primary outcomes of quantitative muscle testing (QMT) arm score and QMT leg score. Secondary strength scores for QMT elbow flexors also showed equivalence between the 2 treatment groups. Overall side effect profiles of height and weight, bone density, cataract formation, blood pressure, and behavior, analyzed at 12 months, did not differ between weekend and daily dosing of prednisone.
CONCLUSIONS: Weekend dosing of prednisone is equally beneficial to the standard daily dosing of prednisone. Analysis of side effect profiles demonstrated overall tolerability of both dosing regimens. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that weekend prednisone dosing is as safe and effective as daily prednisone in preserving muscle strength and preventing body mass index increases in boys with DMD over a 12-month period.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21753160      PMCID: PMC3146308          DOI: 10.1212/WNL.0b013e318227b164

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  33 in total

1.  Clinical evaluator reliability for quantitative and manual muscle testing measures of strength in children.

Authors:  D M Escolar; E K Henricson; J Mayhew; J Florence; R Leshner; K M Patel; P R Clemens
Journal:  Muscle Nerve       Date:  2001-06       Impact factor: 3.217

2.  Validity of body mass index compared with other body-composition screening indexes for the assessment of body fatness in children and adolescents.

Authors:  Zuguo Mei; Laurence M Grummer-Strawn; Angelo Pietrobelli; Ailsa Goulding; Michael I Goran; William H Dietz
Journal:  Am J Clin Nutr       Date:  2002-06       Impact factor: 7.045

3.  High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy.

Authors:  Anne M Connolly; Jeanine Schierbecker; Renee Renna; Julaine Florence
Journal:  Neuromuscul Disord       Date:  2002-12       Impact factor: 4.296

4.  Bone mineral density and fractures in boys with Duchenne muscular dystrophy.

Authors:  C M Larson; R C Henderson
Journal:  J Pediatr Orthop       Date:  2000 Jan-Feb       Impact factor: 2.324

5.  Reliable surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy.

Authors:  Jill E Mayhew; Julaine M Florence; Thomas P Mayhew; Erik K Henricson; Robert T Leshner; Robert J McCarter; Diana M Escolar
Journal:  Muscle Nerve       Date:  2007-01       Impact factor: 3.217

6.  Decreased bone density in ambulatory patients with duchenne muscular dystrophy.

Authors:  Luis F Aparicio; Marguerite Jurkovic; James DeLullo
Journal:  J Pediatr Orthop       Date:  2002 Mar-Apr       Impact factor: 2.324

Review 7.  Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management.

Authors:  Katharine Bushby; Richard Finkel; David J Birnkrant; Laura E Case; Paula R Clemens; Linda Cripe; Ajay Kaul; Kathi Kinnett; Craig McDonald; Shree Pandya; James Poysky; Frederic Shapiro; Jean Tomezsko; Carolyn Constantin
Journal:  Lancet Neurol       Date:  2009-11-27       Impact factor: 44.182

Review 8.  Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care.

Authors:  Katharine Bushby; Richard Finkel; David J Birnkrant; Laura E Case; Paula R Clemens; Linda Cripe; Ajay Kaul; Kathi Kinnett; Craig McDonald; Shree Pandya; James Poysky; Frederic Shapiro; Jean Tomezsko; Carolyn Constantin
Journal:  Lancet Neurol       Date:  2009-11-27       Impact factor: 44.182

9.  Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy.

Authors:  Larry W Markham; Kathi Kinnett; Brenda L Wong; D Woodrow Benson; Linda H Cripe
Journal:  Neuromuscul Disord       Date:  2008-04-23       Impact factor: 4.296

Review 10.  Glucocorticoid corticosteroids for Duchenne muscular dystrophy.

Authors:  A Y Manzur; T Kuntzer; M Pike; A Swan
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23
View more
  55 in total

Review 1.  What can Duchenne Connect teach us about treating Duchenne muscular dystrophy?

Authors:  Richard T Wang; Stanley F Nelson
Journal:  Curr Opin Neurol       Date:  2015-10       Impact factor: 5.710

Review 2.  A systematic review and meta-analysis of glucocorticoid-induced osteoporosis in children.

Authors:  Karen E Hansen; Brian Kleker; Nasia Safdar; Christie M Bartels
Journal:  Semin Arthritis Rheum       Date:  2014-02-11       Impact factor: 5.532

3.  Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study.

Authors:  Luca Bello; Heather Gordish-Dressman; Lauren P Morgenroth; Erik K Henricson; Tina Duong; Eric P Hoffman; Avital Cnaan; Craig M McDonald
Journal:  Neurology       Date:  2015-08-26       Impact factor: 9.910

Review 4.  Growth, pubertal development, and skeletal health in boys with Duchenne Muscular Dystrophy.

Authors:  Leanne M Ward; David R Weber
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2019-02       Impact factor: 3.243

5.  Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients.

Authors:  Yetrib Hathout; Ramya L Marathi; Sree Rayavarapu; Aiping Zhang; Kristy J Brown; Haeri Seol; Heather Gordish-Dressman; Sebahattin Cirak; Luca Bello; Kanneboyina Nagaraju; Terry Partridge; Eric P Hoffman; Shin'ichi Takeda; Jean K Mah; Erik Henricson; Craig McDonald
Journal:  Hum Mol Genet       Date:  2014-07-15       Impact factor: 6.150

6.  Population Pharmacokinetics of Vamorolone (VBP15) in Healthy Men and Boys With Duchenne Muscular Dystrophy.

Authors:  Panteleimon D Mavroudis; John van den Anker; Laurie S Conklin; Jesse M Damsker; Eric P Hoffman; Kanneboyina Nagaraju; Paula R Clemens; William J Jusko
Journal:  J Clin Pharmacol       Date:  2019-02-11       Impact factor: 3.126

7.  Obesity and Endocrine Management of the Patient With Duchenne Muscular Dystrophy.

Authors:  David R Weber; Stasia Hadjiyannakis; Hugh J McMillan; Garey Noritz; Leanne M Ward
Journal:  Pediatrics       Date:  2018-10       Impact factor: 7.124

8.  The cooperative international neuromuscular research group Duchenne natural history study--a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used.

Authors:  Craig M McDonald; Erik K Henricson; R Ted Abresch; Jay J Han; Diana M Escolar; Julaine M Florence; Tina Duong; Adrienne Arrieta; Paula R Clemens; Eric P Hoffman; Avital Cnaan
Journal:  Muscle Nerve       Date:  2013-05-16       Impact factor: 3.217

9.  Δ-9,11 modification of glucocorticoids dissociates nuclear factor-κB inhibitory efficacy from glucocorticoid response element-associated side effects.

Authors:  Andreas R Baudy; Erica K M Reeves; Jesse M Damsker; Christopher Heier; Lindsay M Garvin; Blythe C Dillingham; John McCall; Sree Rayavarapu; Zuyi Wang; Jack H Vandermeulen; Arpana Sali; Vanessa Jahnke; Stephanie Duguez; Debra DuBois; Mary C Rose; Kanneboyina Nagaraju; Eric P Hoffman
Journal:  J Pharmacol Exp Ther       Date:  2012-06-28       Impact factor: 4.030

10.  Disruption of a key ligand-H-bond network drives dissociative properties in vamorolone for Duchenne muscular dystrophy treatment.

Authors:  Xu Liu; Yashuo Wang; Jennifer S Gutierrez; Jesse M Damsker; Kanneboyina Nagaraju; Eric P Hoffman; Eric A Ortlund
Journal:  Proc Natl Acad Sci U S A       Date:  2020-09-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.